1 Development of disordered eating behaviors and comorbid depressive symptoms in 2 adolescence: neural and psychopathological predictors

13

14 1 Centre for Population Neuroscience and Precision Medicine (PONS), Institute of Psychiatry, Psychology & Neuroscience, Social, Genetic and Developmental Psychiatry Centre, King's College London, De Crespigny Park, London, SE5 8AF, United Kingdom; 2 Section of Eating Disorders, Department of Psychological Medicine, King's College London, London, United Kingdom; 3 Institute of Science and Technology for Brain-Inspired Intelligence, Fudan University, Shanghai, China; 4 Ministry of Education-Key Laboratory of Computational Neuroscience and Brain-Inspired Intelligence, Fudan University, Shanghai, China; 5

 Developmental Psychopathology Lab, Department of Psychology, King's College London, London, United Kingdom; 6 Department of Child and Adolescent Psychiatry and Psychotherapy, Central Institute of Mental Health, Medical Faculty Mannheim, Heidelberg University, Square J5, 68159 Mannheim, Germany; 7 Department of Neuroimaging, Institute of Psychiatry, Psychology & Neuroscience, King's College London, United Kingdom; 8 Discipline of Psychiatry, School of Medicine and Trinity College Institute of Neuroscience, Trinity College Dublin, Dublin, Ireland; 9 Department of Cognitive and Clinical Neuroscience, Central Institute of Mental Health, Medical Faculty Mannheim, Heidelberg University, Square J5, Mannheim, Germany; 10 Department of Psychology, School of Social Sciences, University of Mannheim, 68131 Mannheim, Germany; 11 NeuroSpin, CEA, Université Paris-Saclay, F-91191 Gif-sur- Yvette, France; 12 Departments of Psychiatry and Psychology, University of Vermont, 05405 Burlington, Vermont, USA; 13 Sir Peter Mansfield Imaging Centre School of Physics and Astronomy, University of Nottingham, University Park, Nottingham, United Kingdom; 14 Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt- Universität zu Berlin, and Berlin Institute of Health, Department of Psychiatry and Psychotherapy, Campus Charite Mitte, Chariteplatz 1, Berlin, Germany; 15 Physikalisch- Technische Bundesanstalt (PTB), Braunschweig and Berlin, Germany; 16 INSERM U A10 "Developmental Trajectories & Psychiatry"; Université Paris-Saclay, Ecole Normale Supérieure Paris-Saclay, CNRS, Centre Borelli; Gif-sur-Yvette, France; 17 National Institute of Mental Health / NIH, 15K North Drive, Bethesda MD, 20892, USA; 18 Department of Social and Health Care, Psychosocial Services Adolescent Outpatient Clinic Kauppakatu 14, Lahti, Finland; 19 MSB

 Medical School Berlin, Calandrellistr. 1-9, 12247 Berlin, Germany; 20 Institut National de la Santé et de la Recherche Médicale, INSERM Unit 1000 "Neuroimaging & Psychiatry", Université Paris Saclay, Université Paris Descartes; Sorbonne Université; and AP-HP, Department of Child and Adolescent Psychiatry, Pitié-Salpêtrière Hospital, Paris, France; 21 Department of Child and Adolescent Psychiatry and Psychotherapy, University Medical Centre Göttingen, von-Siebold- Str. 5, 37075, Göttingen, Germany; 22 Bloorview Research Institute, Holland Bloorview Kids Rehabilitation Hospital and Departments of Psychology and Psychiatry, University of Toronto, Toronto, Ontario, M6A 2E1, Canada; 23 Department of Psychiatry and Neuroimaging Center, Technische Universitat Dresden, Dresden, Germany; 24 School of Psychology and Global Brain Health Institute, Trinity College Dublin, Ireland; 25 Department of Psychiatry and Psychotherapy, Campus Charite Mitte, Humboldt University, Berlin, Germany and Institute for Science and Technology of Brain-inspired Intelligence (ISTBI), Fudan University, Shanghai, China; 26 The Eating Disorders Service, Maudsley Hospital, South London and Maudsley NHS Foundation Trust, London, UK; 27 Institute of Medical Psychology and Medical Sociology, University Medical Center Schleswig Holstein, Kiel University, Kiel, Germany.

 Address correspondence to Dr Sylvane Desrivières, Social, Genetic and Developmental Psychiatry Centre, Institute of Psychiatry, Psychology & Neuroscience, King's College London, De Crespigny Park, London SE5 8AF, United Kingdom [\(sylvane.desrivieres@kcl.ac.uk\)](mailto:sylvane.desrivieres@kcl.ac.uk).

21 *These authors contributed equally to this work.

-
- Running title: Predictors of disordered eating and depression
-
- Keywords: eating disorders, depression, attention deficit hyperactivity disorder, conduct
- disorder, biomarkers, grey matter volume

Abstract

BACKGROUND:

 Eating disorders are common in adolescence, devastating and strongly comorbid with other psychiatric disorders. Yet, little is known about their etiology to develop effective preventive measures.

METHODS:

 Longitudinal assessments of disordered eating behaviors (DEBs; binge-eating, purging and dieting) and comorbid psychopathology were measured in 1,386 adolescents from the IMAGEN study. Development of DEBs and associated mental health problems were investigated by comparing participants who reported symptoms at ages 16 or 19, but not at age 14 to asymptomatic controls. Voxel-based morphometry and psychopathological differences at age 14 were investigated to identify risk factors for the development of DEBs and associated mental health problems.

RESULTS:

 DEBs and depressive symptoms developed together. Emotional and behavioral problems, including symptoms of attention deficit hyperactivity disorder (ADHD) and conduct disorder (CD), predated their development. Alterations in fronto-striatal brain areas also predated the development of DEBs and depressive symptoms. Specifically, development of binge-eating was predicted by higher grey matter volumes in the right putamen/globus pallidus at age 14. Conversely, development of purging and depressive symptoms was predicted by lower

Introduction

 Eating disorders (EDs), including anorexia nervosa (AN), bulimia nervosa (BN) and binge eating disorder (BED), are severe psychiatric disorders that affect up to 15% of young women and 3% of young men (1). The peak age of onset is from mid adolescence into emerging adulthood (age 15 to 19), i.e. at a developmentally sensitive time (2). EDs are characterized by disordered eating behaviors (DEBs), including dietary restriction, binge-eating and purging. Varying combinations of these DEBs occur in different EDs and across the weight spectrum from severely underweight to obese. Crucially, subclinical DEBs whose prevalence is particularly high (14%-22%) (3, 4) in children and adolescents predict development of full-syndrome EDs in later life (5, 6). Thus, identifying causal risk factors of DEBs and understanding their development is key to identifying high-risk groups and developing prevention strategies.

 Comorbid disorders are common in EDs. These include mood, anxiety and substance use disorders, which are common across all EDs (7) and impulse-control disorders like Attention Deficit Hyperactivity Disorder (ADHD), oppositional-defiant and conduct disorder (CD), which are prevalent in BN and BED (7, 8). Longitudinal studies have demonstrated that emotional and behavioral problems, including ADHD (9, 10) and CD symptoms (11) are risk factors of developing EDs. ADHD in childhood also confers higher risk of developing depression in adolescence/young adulthood (12, 13), suggesting that EDs and comorbid depression have shared psychopathological risk factors.

neuroimaging methods by showing that differences in neural responses to inhibitory control

comorbid mental health problems. We have recently demonstrated the value of longitudinal

 can be detected 2 years before the onset of binge-eating or purging behaviors (23). Altogether, these findings suggest that advances in understanding and prevention of EDs are likely to benefit from an approach using dimensional and longitudinal assessments of DEBs, focusing on underlying neurobiological substrates (24).

 Building up on this, here we use the longitudinal design of IMAGEN, a large, prospective cohort of European adolescents, to investigate early psychopathological and neuroanatomical risk factors for the development of DEBs and comorbid mental health problems. Hypothesizing that structural brain alterations underlie shared risk for developing DEBs and comorbid mental health problems, we performed longitudinal and mediation analyses to lend insight into the etiology of EDs and evaluate underlying neural mechanisms through which psychopathological risk factors relate to the development of DEBs and comorbid mental health symptoms.

Methods and Materials

Participants

 Questionnaire and neuroimaging data were obtained from IMAGEN – a longitudinal cohort acquired from 8 study sites in Europe. Each site received approval from their local research ethics committee. Written assent from the adolescents and written consent from the parents were obtained prior to participation. See (25) for details of the recruitment and assessment methods. In this study, we used questionnaire data acquired at ages 14, 16 and 19, and neuroimaging data acquired at age 14.

Psychopathological assessments

 Eating disorder symptoms: Binge-eating, purging and dieting behaviors were assessed using the self-reports from the Development and Wellbeing Assessment (DAWBA) (26, 27). We used binary variables to indicate the presence or absence of binge-eating, purging and dieting symptoms at each age. A positive response to question 15, related to eating a large amount of food and losing control over eating was used to indicate the presence of binge-eating. A positive response to any of 3 questions (1c, 18f and 18g) related to self-induced vomiting or taking pills/medicines to lose weight was used to indicate the presence of purging behavior. A score of 3 (answer for 'a lot') for any of the 3 questions (question 18a, 18b and 18c) related to eating less at meals, skipping meals and fasting was used to indicate the presence of dieting behavior. Dieting behaviors were also defined with more relaxed criteria (score ≥ 2), detailed in the Supplemental Information.

 We categorized participants into groups who developed DEBs over time and those who remained asymptomatic based on each of the 3 DEBs. The "binge-eating developers" did not report binge-eating symptoms at age 14 but developed binge-eating symptoms at age 16 or 19. The "non-bingers" did not report binge-eating at any of the 3 ages. In the same manner we defined "purging developers", "non-purgers", "dieting developers" and "non-dieters". Besides these, we compared individuals who did not report any DEB at age 14 but reported at least one DEB at ages 16 or 19 ("any DEB developers") to individuals without any DEB at any age ("non-DEB" group). We also defined groups based on Bartholdy et al. (2019) (23) who combined binge-eating and purging symptoms together. We report these as "binge-eating or purging (BoP)", defining developers, maintainers and recoverers based on their longitudinal development (See Supplemental Methods).

 As expected, these DEB developers and their asymptomatic controls showed significant sex differences (Supplemental Table S1). To obtain sex-balanced groups of cases and controls, each developer group and the corresponding asymptomatic group were matched for sex and acquisition site, by using the propensity score matching method implemented in the Matchit toolbox (28). Details are provided in the Supplemental Information.

 Emotional and behavioral problems: The Strengths and Difficulties Questionnaire (SDQ) (29) was used to measure participants' emotional and behavioral symptoms. We used self-report scores at age 14 for the following 4 subscales: emotional symptoms, conduct problems (i.e., CD symptoms), hyperactivity/inattention (i.e., ADHD symptoms) and peer relationship problems.

 Mental health symptoms: Computer-generated DAWBA diagnoses (DAWBA bands) (30) derived from the self-report questionnaire were used to measure the severity of psychopathology-related symptoms at the 3 ages. DAWBA bands comprised up to 6 levels (from 0 to 5) and indicated the probability of having a disorder (from <0.1% to >70% probability of DSM-IV based diagnoses). IMAGEN being a normative cohort, we focused on common mental health problems in our cohort, as defined by prevalence ≥ 5% at age 19 for participants scoring 3 and above (15%+ risk according to the DAWBA bands) for the disorder. DAWBA bands for depression and generalized anxiety disorder (GAD) passed this threshold and their associations with DEBs were investigated. We defined a group of "depression developers" (N=290) whose depression scores were below 3 at age 14, and above or equal to 3 at ages 16 or 19. This was compared to controls (labeled as "non-depression", N=857) whose depression scores were below 3 across the 3 ages. Similarly, we defined "anxiety developers" (N=203) and "non-anxiety" (N=1107).

Body mass index (BMI) and medication: BMI (kg/m²) at age 14 was derived from height and weight measurements and transformed to age- and sex-adjusted z-scores based on the Centre for Disease Control and Prevention Growth Chart (31). A binary variable was created to indicate whether participants took any prescription medicine in the past 30 days based on the Timeline Followback Interview (32).

Structural Magnetic resonance imaging (MRI) acquisition and processing

 MRI images were acquired with 3T MRI scanners (Siemens, Philips, General Electric) across all IMAGEN sites. A 3D magnetization scan based on the ADNI protocols [\(http://adni.loni.usc.edu/methods/documents/mri-protocols/\)](http://adni.loni.usc.edu/methods/documents/mri-protocols/) was used to acquire T1- weighted structural images. Quality control was performed through visual inspection to exclude images with movement artefacts, brace artefacts or field inhomogeneities. Voxel- based morphometry (VBM) analyses were conducted using the VBM8 toolbox (http://www.neuro.uni-jena.de/vbm/) in SPM8 (https://www.fil.ion.ucl.ac.uk/spm/) to obtain grey matter volumes (GMVs), as detailed in the Supplemental Information. Intracranial volume (ICV), estimated in VBM8 by summing up grey matter, white matter and CSF volumes, was used as a covariate in all the analyses involving GMVs (33).

Statistical Analyses

 DEB development and comorbid mental health symptoms. To investigate if DEBs and mental 21 health symptoms co-developed, we tested for associations between the development of DEBs and the development of depression and anxiety symptoms while controlling for sex, acquisition site and depression or anxiety symptoms at age 14. These analyses were performed with the whole sample (i.e., without matching for sex and acquisition site).

 Emotional and behavioral problems as predictors of DEBs. We investigated whether SDQ subscales at age 14 could predict DEB development using Firth logistic regression models (34) controlling for sex and acquisition site. Potentially confounding effects of BMI were tested by further controlling significant associations for BMI at age 14. The *p* values were corrected using the Holm-Bonferroni method. We also investigated whether emotional and behavioral problems that predicted DEBs also predicted the development of depression and anxiety symptoms, controlling for depression or anxiety symptoms at age 14, sex and acquisition site.

 Voxel-wise GMV analyses. We investigated whether structural brain differences at age 14 predated the development of DEBs. Generalized linear models (GLM) in SPM12 involved GMVs as the dependent variable, and the DEB group (developers vs. controls) as an independent variable. We tested whether shared anatomical differences underlay the development of DEBs and comorbid mental health problems as follows. First, we investigated voxel-wise GMV associations with development of depression and anxiety symptoms. We then tested if the associated brain regions overlapped with those associated with DEB development. We also 20 investigated voxel-wise GMV associations with each of the 4 SDQ subscales at age 14. Control variables included in all analyses were sex, acquisition sites and total intracranial volumes (ICV). Depression or anxiety symptoms at age 14 were also included as covariates in analyses involving development of depression and anxiety. The threshold for all the neuroimaging analyses was *p*<0.001 uncorrected at the voxel level, and *p*<0.05 corrected for family wise error (FWE) at the cluster level.

 Mediation analyses. We tested whether the brain regions associated with SDQ subscales mediated the associations between SDQ subscales at age 14 and development of DEBs and comorbid depression/anxiety symptoms. The brain regions associated with SDQ subscales were used as ROIs. Control variables included sex, acquisition site and ICV. The mental health symptom at age 14 was controlled for when investigating the development of depression/anxiety. The continuous variables were transformed to *z*-scores. Confidence intervals for the mediation effect were estimated from 5000 bootstrap samples by using the PROCESS macro (v3.2, http://processmacro.org) in SPSS (v25, IBM Corporation).

Results

 CD symptoms at age 14 predicted the development of purging (OR = 1.35, *p* = 1.6E-03 for ADHD symptoms; OR = 1.43, *p* = 8.5E-05 for CD symptoms; Table 1) and BoP behaviors (OR = 1.28, *p* $3 = 4.7E-03$ for ADHD symptoms; OR = 1.40, $p = 1.0E-04$ for CD symptoms; Supplemental Table S4). CD symptoms at age 14 also predicted the maintenance of BoP (OR = 1.69, *p* = 5.8E-04, Supplemental Table S4) and the development of "any DEB" (OR = 1.36, *p* = 3.9E-03, Supplemental Table S5). These associations remained significant after controlling for BMI. Further analyses of the association with ADHD symptoms indicated that both the hyperactivity- impulsivity and inattention components contributed to the association with future purging behaviors (OR = 1.33, *p* = 2.5E-03 and OR = 1.23, *p*= 0.028 for hyperactivity-impulsivity and inattention, respectively). A significant predictor for dieting development was found only by using a more relaxed criterion for dieting (CD symptoms, OR = 1.27, *p* = 0.013, Supplemental Results).

 Emotional and behavioral problems at age 14 also predicted the development of depression and anxiety at later ages (Table 2). More specifically, emotional problems (OR = 1.56, *p*= 3.7E-16 04) and ADHD symptoms (OR = 1.24, $p = 0.045$) predicted the development of anxiety symptoms (controlling for depressive symptoms at ages 14, 16 and 19), while CD symptoms specifically predicted the development of depressive symptoms (OR = 1.22, *p* = 0.025, controlling for anxiety symptoms at ages 14, 16 and 19).

Structural brain differences at age 14 predate the development of DEBs and depressive symptoms

 Whole brain VBM analyses demonstrated that binge-eating developers had higher GMVs in a subcortical cluster comprising the right putamen and globus pallidus at age 14 (Figure 1A & Supplemental Table S6). Conversely, purging developers had lower GMVs in a cluster encompassing the medial OFC (mOFC), the gyrus rectus, the anterior and middle cingulate cortex (ACC and MCC), the left dorsomedial and dorsolateral prefrontal cortex (Figure 1B). Similarly, BoP developers had smaller GMVs at age 14 in the mOFC, gyrus rectus, ACC and MCC (Figure 1C). No significant GMV differences were associated with dieting developers, "any DEB" developers, BoP maintainers or BoP recoverers. Repeating analyses by controlling for BMI at age 14, or removing participants who took any medication in the past 30 days, or removing individuals reporting other DEBs at age 14 did not substantially change main associations (see Supplemental Results, Tables S6-S7 & Figures S3-S4). However, repeating the VBM analyses in 14 girls only did not yield significant results on the whole brain level.

 We tested if brain regions associated with DEB development were also associated with developing symptoms of depression or generalized anxiety. Whole brain VBM analyses demonstrated that depression developers had lower GMVs in two clusters comprising the medial and left lateral OFC, ACC, MCC, the supplementary motor area, the dorsomedial PFC 20 and left dorsolateral PFC (Figure 1D & Supplemental Table S8). These clusters overlapped with 21 those associated with purging development in the ACC, MCC, mOFC, dorsomedial and left

Brain structure underlying CD and ADHD symptoms mediate the development of purging and

comorbid depressive symptoms

 The analyses presented above suggested that neural correlates of SDQ traits – should they be detected – may serve as potential brain-based mediators for DEBs. To test this, we first analyzed associations between GMVs and DEB-associated SDQ measures at age 14, using the whole sample of 1594 participants. Higher CD symptoms were associated with lower grey matter volumes in the ACC, mOFC and the superior and middle frontal gyrus (Figure 2A & Supplemental Table S6). The ACC/mOFC region partly overlapped with those associated with purging development (262 voxels), BoP development (59 voxels) and depression development (74 voxels, Figure 2A). In contrast, higher ADHD symptoms were significantly associated with lower GMVs in a cluster encompassing the mOFC, gyrus rectus and anterior orbital gyrus (Figure 2B & Supplemental Table S6). These regions overlapped with those associated with purging development (461 voxels), BoP development (853 voxels) and depression development (148 voxels, Figure 2B). No significant GMV associations were observed for emotional problems.

 Next, we investigated whether the GMV differences identified above mediated the relationship between CD or ADHD symptoms at age 14 and the development of purging, BoP and depression. Brain regions associated with CD symptoms (ACC/mOFC) and ADHD symptoms (labelled as OFC) were used as ROIs. Lower GMVs in the ACC/mOFC mediated the relationship between CD symptoms and the development of purging (indirect effect = 0.021, bootstrap 95% CI = 7.3E-04-0.056) and depression (indirect effect = 0.021, bootstrap 95% CI = 0.0023-0.050, Figure 3A). Likewise, lower GMVs in the OFC mediated the association between ADHD symptoms and the development of purging (indirect effect = 0.024, bootstrap 95% CI = 0.0016- 0.058) and depression (indirect effect = 0.025, bootstrap 95% CI = 0.0039-0.053, Figure 3B). Similarly, these ROIs significantly mediated the effects of CD and ADHD symptoms on the development of BoP (Supplemental Figure S5). No significant mediation effects were found for the development of anxiety symptoms.

Discussion

 Our longitudinal analyses, aimed at identifying early predictors of the development of DEBs and comorbid depression/anxiety symptoms in adolescence, identified shared neural substrates underlying the psychopathological risk for the development of DEBs and depression. We show that higher GMVs in the putamen and globus pallidus and emotional difficulties predate the development of binge-eating. We similarly demonstrated that lower GMVs in frontal and cingulate cortices, and ADHD and CD symptoms were associated with development of purging, BoP and depression. Importantly, the lower GMVs associated with ADHD and CD symptoms mediated the relationships between these symptoms and future purging, BoP and depression. These results support previous research showing high prevalence of ADHD, CD, depression and GAD in EDs, particularly in bulimia nervosa (7, 8), and extend our knowledge of 12 the neural underpinning of these disorders.

14 We have identified several neural substrates as early markers for the development of DEBs. Lower GMVs across the prefrontal cortex, including the mOFC, ACC, MCC, the dorsomedial and dorsolateral PFC are early indicators for the development of purging and BoP behaviors. Our mediation analyses also implicate the OFC and ACC/mOFC in the neural mechanisms underlying the associations between ADHD and CD symptoms and future purging and BoP behaviors. These results are consistent with previous suggestions of overlapping neural circuits involved in cognitive control and reward systems between ADHD and EDs (35). For example, reduced GMVs in the OFC are consistently found in ADHD patients (36), which correlate with their functional impairments in emotion regulation, reward-related decision making and control of motivation (37). Shared neurobiological mechanisms (35) are further supported by observations of overlapping treatment responses to psychostimulant medications in ADHD and BN/BED patients (38, 39).

 Youths with ADHD are at higher risk of developing depression (40), and their common neurobiological mechanisms have been suggested (41). For example, resting-state functional connectivity between the left OFC and left hippocampus is reduced in children with ADHD; furthermore, this connectivity is also negatively associated with depressive symptom severity in children with ADHD (41). However, research on neurobiological mechanisms of ADHD and depression has been largely separate, and the neural mediators between the two have been unclear until now. Our results highlight structural differences in the OFC to be a neural substrate that confers higher risk for depression in youths with greater ADHD symptoms. As the OFC plays important roles in emotion regulation (42), our result concurs with the finding that emotion regulation deficiencies mediate the association between ADHD and depressive symptoms (43, 44). By demonstrating that reduced GMVs in the OFC mediate the effect of ADHD symptoms on both future purging and depressive symptoms, our results further suggest that ADHD, depression and EDs may have a common neurobiological basis.

 The observed reduced GMVs in the ACC/mOFC was consistent with recent neuroimaging findings in CDs (45). Both the ACC and mOFC are involved in reward-based decision making by encoding action-reward associations (46, 47) and also in top-down emotion regulation (48). Our results suggest that impairments in reward processing and/or emotion regulation may underlie the link between conduct problems and future purging behaviors and depression.

 Other brain regions associated with purging/BoP symptoms, i.e., the dorso-lateral, dorso- medial PFC and ACC, are part of the inhibition control system responsible for regulatory control and response inhibition (49). Hypoactivation of these regions has been associated with substance use and behavioral addictions (49). In line with our findings, a cluster in the ACC was also found by Bartholdy *et al.* (2019) to be hypo-activated in BoP developers during successful (vs. failed) response inhibition (23). Conversely, activating the dorsolateral PFC with high- frequency repetitive transcranial magnetic stimulation (rTMS) can reduce food craving and binge-eating frequencies in bulimic disorders (50). Based on these findings, lower GMVs in the dorsolateral and dorsomedial PFC in purging developers suggest weakened functions in inhibition control, which may underlie their vulnerability to impulsive behaviors like purging.

 The neural substrates associated with development of binge-eating encompassed the right putamen and globus pallidus, with greater GMVs implicating higher risk. Previous studies of ED patients found reduced GMVs in the bilateral striatum in BN (18) and BED (51, 52) and 21 increased GMVs in the OFC for BN (18), which is at odds with our findings. The differences may be due to sample characteristics and the study design, previous neuroimaging studies being cross-sectional and involving adult patients with EDs. In comparison, the present study investigated onset of DEBs symptoms in a longitudinal cohort of healthy adolescents. It is possible that higher putamen volumes confer risk for future binge-eating, while reduced volumes ensue from suffering these conditions over the years. Clearly, more longitudinal developmental research is needed to study abnormal developmental patterns associated with DEBs and depression.

Strengths and Limitations

 Our study has several strengths. First, it is one of the only two longitudinal studies (23) to examine the neurobiological predictors of DEBs in a well-characterized population-based adolescent cohort. The sample size and multi-modality of the data (questionnaires and neuroimaging) were other strengths of our study. Matching sex and acquisition sites between case and control groups removed confounding effects from these variables.

 There are also several weaknesses to consider. First, the very limited number of males in the case groups did not enable us to investigate sex-specific effects. Second, the effects of other confounding factors (e.g., parental and social) were not ruled out. Thirdly, DEBs were assessed through self-reports only. Fourthly, it cannot be concluded that the risk factors identified here are associated exclusively with a single DEB as our analyses did not exclude coexisting DEBs. Fifth, the mediation analysis included two variables (SDQ symptoms and brain structure) assessed at one time point and a third variable (development of DEB or depression) assessed 2 at another, rather than all variables assessed at separate time points. Lastly, as we we did not find significant structural brain risk factors for dieting, the neurobiological risk factors for restrictive eating behaviors remain unclear (53).

 Overall, our study highlights psychopathological traits that may be causal risk factors of DEBs, including emotional problems, ADHD and CD symptoms, which can help identify high-risk groups for targeted prevention. The identification of neurobiological substrates of DEBs and comorbid depression, specifically in the OFC and ACC, provides promising therapeutic strategies for EDs and comorbid conditions (54, 55).

Acknowledgements

 This work received support from the following sources: the Medical Research Council and Medical Research Foundation (grants MR/R00465X/1 and MRF-058-0004-RG-DESRI: 'ESTRA: Neurobiological underpinning of eating disorders: integrative biopsychosocial longitudinal analyses in adolescents'; MR/S020306/1 and MRF-058-0009-RG-DESR-C0759: 'Establishing causal relationships between biopsychosocial predictors and correlates of eating disorders and their mediation by neural pathways'), the European Union-funded FP6 Integrated Project IMAGEN (Reinforcement-related behavior in normal brain function and psychopathology) (LSHM-CT- 2007-037286), the Horizon 2020 funded ERC Advanced Grant 'STRATIFY' (Brain network based stratification of reinforcement-related disorders) (695313), ERANID (Understanding the Interplay between Cultural, Biological and Subjective Factors in Drug Use Pathways) (PR-ST-0416-10004), BRIDGET (JPND: Brain Imaging, cognition Dementia and next generation Genomics) (MR/N027558/1), Human Brain Project (HBP SGA 2, 785907), the FP7 project MATRICS (603016), the Medical Research Council Grant 'c-VEDA' (Consortium on Vulnerability to Externalizing Disorders and Addictions) (MR/N000390/1), the National Institute for Health Research (NIHR) Biomedical Research Centre at South London and Maudsley NHS Foundation Trust and King's College London, the Bundesministerium für Bildung und Forschung (BMBF grants 01GS08152; 01EV0711; Forschungsnetz AERIAL 01EE1406A, 01EE1406B), the Deutsche Forschungsgemeinschaft (DFG grants SM 80/7-2, SFB 940/2, NE 1383/14-1), the National Institutes of Health (NIH) funded ENIGMA (grants 5U54EB020403-05

 and 1R56AG058854-01). Further support was provided by grants from: the ANR (ANR-12- SAMA-0004, AAPG2019–GeBra), the Eranet Neuron (AF12-NEUR0008-01–WM2NA; and ANR- 18-NEUR00002-01–ADORe), the Fondation de France (00081242), the Fondation pour la Recherche Médicale (DPA20140629802), the Mission Interministérielle de Lutte-contre-les- Drogues-et-les-Conduites-Addictives (MILDECA), the Assistance-Publique-Hôpitaux-de-Paris and INSERM (interface grant), Paris Sud University IDEX 2012, the Fondation de l'Avenir (grant AP-RM-17-013), the Fédération pour la Recherche sur le Cerveau; the National Institutes of Health, Science Foundation Ireland (16/ERCD/3797), U.S.A. (Axon, Testosterone and Mental Health during Adolescence; RO1 MH085772-01A1), and by NIH Consortium grant U54 EB020403, supported by a cross-NIH alliance that funds Big Data to Knowledge Centers of Excellence. Ulrike Schmidt is supported by a Senior Investigator award from the National Institute for Health Research (NIHR). This research was reviewed by a team with experience of mental health problems and their carers who have been specially trained to advise on research proposals and documentation through the Young Person's Mental Health Advisory Group: a free, confidential service in England provided by the National Institute for Health Research Maudsley Biomedical Research Centre via King's College London.

 IMAGEN Consortium authors: Tobias Banaschewski, M.D., Ph.D., Gareth J. Barker, Ph.D., Arun L.W. Bokde, Ph.D., Erin Burke Quinlan, Ph.D., Sylvane Desrivières, Ph.D., Herta Flor, Ph.D., Antoine Grigis, Ph.D., Hugh Garavan, Ph.D., Penny Gowland, Ph.D., Andreas Heinz, M.D., Ph.D.,

 Other IMAGEN consortium members: Uli Bromberg, Ph.D., University Medical Centre Hamburg-Eppendorf, House W34, 3.OG, Martinistr. 52, 20246, Hamburg, Germany. Vincent Frouin, Ph.D., NeuroSpin, CEA, Université Paris-Saclay, F-91191 Gif-sur-Yvette, France. Eric Artiges, M.D., Ph.D., Institut National de la Santé et de la Recherche Médicale, INSERM Unit 1000 "Neuroimaging & Psychiatry", University Paris Sud, University Paris Descartes - Sorbonne Paris Cité; and Psychiatry Department 91G16, Orsay Hospital, France. Herve Lemaitre, Ph.D, NeuroSpin, CEA, Université Paris-Saclay, F-91191 Gif-sur-Yvette, France; Institut National de la Santé et de la Recherche Médicale, UMR 992 INSERM, CEA, Faculté de médecine, Université Paris-Sud, Université Paris-Saclay, NeuroSpin, F-91191 Gif-sur-Yvette, France. Sabina Millenet, Dipl.-Psych., Department of Child and Adolescent Psychiatry and Psychotherapy, Central Institute of Mental Health, Medical Faculty Mannheim, Heidelberg University, Square J5, 68159 Mannheim, Germany.

Disclosures

 Dr. Banaschewski served in an advisory or consultancy role for Lundbeck, Medice, Neurim Pharmaceuticals, Oberberg GmbH, Shire. He received conference support or speaker's fee by Lilly, Medice, Novartis and Shire. He has been involved in clinical trials conducted by Shire & Viforpharma. He received royalties from Hogrefe, Kohlhammer, CIP Medien, Oxford University Press. The present work is unrelated to the above grants and relationships. Dr. Barker has received honoraria from General Electric Healthcare for teaching on scanner programming courses. The other authors report no biomedical financial interests or potential conflicts of interest.

References

 8. Yao S, Kuja-Halkola R, Martin J, Lu Y, Lichtenstein P, Norring C, et al. (2019): Associations Between Attention-Deficit/Hyperactivity Disorder and Various Eating Disorders: A Swedish Nationwide Population Study Using Multiple Genetically Informative Approaches. Biol Psychiatry 86:577-586.

 9. Yilmaz Z, Javaras KN, Baker JH, Thornton LM, Lichtenstein P, Bulik CM, et al. (2017): Association Between Childhood to Adolescent Attention Deficit/Hyperactivity Disorder Symptom Trajectories and Late Adolescent Disordered Eating. J Adolesc Health 61:140-146.

10. Yoshimasu K, Barbaresi WJ, Colligan RC, Voigt RG, Killian JM, Weaver AL, et al. (2012):

 Childhood ADHD is strongly associated with a broad range of psychiatric disorders during adolescence: a population-based birth cohort study. J Child Psychol Psychiatry 53:1036-1043.

11. Hilbert A, Pike KM, Goldschmidt AB, Wilfley DE, Fairburn CG, Dohm FA, et al. (2014): Risk

factors across the eating disorders. Psychiatry Res 220:500-506.

12. Chronis-Tuscano A, Molina BS, Pelham WE, Applegate B, Dahlke A, Overmyer M, et al.

(2010): Very early predictors of adolescent depression and suicide attempts in children with

attention-deficit/hyperactivity disorder. Arch Gen Psychiatry 67:1044-1051.

 13. Biederman J, Ball SW, Monuteaux MC, Mick E, Spencer TJ, Mc CM, et al. (2008): New insights into the comorbidity between ADHD and major depression in adolescent and young adult females. J Am Acad Child Adolesc Psychiatry 47:426-434.

14. Smith DG, Robbins TW (2013): The neurobiological underpinnings of obesity and binge

eating: a rationale for adopting the food addiction model. Biol Psychiatry 73:804-810.

Norwegian samples. Soc Psychiatry Psychiatr Epidemiol 46:521-532.

Figure Legends

 FIGURE 1. Structural brain associations with the development of binge-eating (A), purging (B), binge-eating or purging (BoP, C) and depressive symptoms (D). The bar plots show the regional means of GMVs, adjusted by sex, acquisition site and total intracranial volumes. Error bars represent standard errors. Statistical parametric maps were thresholded at voxel-level p<0.001 (uncorrected) and cluster-level p<0.05 (FWE corrected). Overlapping brain regions associated with the development of purging and depressive symptoms are presented in E. Overlapping brain regions for the development of BoP and depressive symptoms are presented in F. The 3D rendered views are generated by MRIcroGL [\(https://www.mccauslandcenter.sc.edu/mricrogl/\)](https://www.mccauslandcenter.sc.edu/mricrogl/). 12 FIGURE 2. Grey matter volume associations with CD symptoms (A, negative association) and ADHD symptoms (B, negative association) at age 14. Statistical parametric maps were thresholded at voxel-level p<0.001 (uncorrected) and cluster-level p<0.05 (FWE corrected).

15 The columns to the right show overlapping brain regions associated with the development of purging, BoP and depressive symptoms.

18 FIGURE 3. Results for the mediation analysis, using the ACC/mOFC ROI linked to CD symptoms (A) and the OFC ROI linked to ADHD symptoms (B) as mediators. For analyses on the development of purging, control variables included sex, acquisition sites and the total

- intracranial volume. For analyses on the development of depression (blue dashed lines), the
- depression symptom at age 14 was involved as an additional control variable. ROI: region of
- interest; CI: confidence interval; ACC: anterior cingulate cortex; OFC: orbitofrontal cortex.

1 Tables

2 Table 1. Psychopathological predictors of DEB symptoms

3 The p values shown in bold survived the Holm-Bonferroni correction, correcting for 12 tests (3 DEBs ×

4 4 SDQ subscales). Significant associations were further controlled for BMI. DEB: disordered eating

5 behavior.

6

2 Table 2. Psychopathological predictors for the development of depression and generalized

3 anxiety symptoms

4 The p values shown in bold survived the Holm-Bonferroni correction, correcting for 6 tests (2 mental

5 health symptoms × 3 SDQ subscales). Significant associations were further controlled for the other

6 mental health symptom at ages 14, 16 and 19 (i.e., controlling depression development for anxiety

7 symptoms at all ages, and vice-versa).

8

9

10